Arginase inhibition prevents the low shear stress-induced development of vulnerable atherosclerotic plaques in ApoE−/− mice

Diminazene enhances stability of atherosclerotic plaques in ApoE-deficient mice

“…Such distinct patterns of shear stress induce atherosclerotic plaques with different compositions. LSS-induced plaques present features of vulnerable plaques, whereas OSS-induced plaques display a more stable phenotype [5,18,28,29]. …”

“…The cast was implanted as previously described [18,29]. Briefly, the animals were anesthetized by isoflurane inhalation, and the anterior cervical triangles were accessed by a sagittal anterior neck incision.…”

Cinnamide Derivatives as Mammalian Arginase Inhibitors: Synthesis, Biological Evaluation and Molecular Docking

“…Over the last few decades, interest has grown concerning the use of arginase for therapeutic uses. Indeed, the use of arginase inhibitors has proven to be beneficial in various pathophysiological states such as hypertension [6], erectile dysfunction [7], pulmonary hypertension [8], atherosclerosis [9], diabetic renal injury [10], asthma and allergic rhinitis [11], myocardial ischemia-reperfusion injury [12], wound healing [13], and cancer [14]. The first generation of arginase inhibitors comprised analogs of N ω -hydroxy- l -arginine (NOHA), the intermediate in the production of NO from l -arginine by NOS [15,16].…”

Label-free Quantitative Urinary Proteomics Identifies the Arginase Pathway as a New Player in Congenital Obstructive Nephropathy

“…Arginase activity represents a possible route of the L-arginine metabolism (51) and has already been associated to pathogenesis of various disorders such as allergic asthma, airway inflammation, diabetes, vascular dysfunction, and atherosclerosis (34,(52)(53)(54)(55)(56)(57), among others. Data from our studies on the animal model of obstructive nephropathy show the potential ability to up-regulate L-arginine transport (via Cat transporters) and to direct its metabolism to L-proline via "the pro-fibrotic arginase pathway" (Fig.…”